Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Nuvalent Inc (NUVL) Price & Performance

YieldMax AMZN Option Income Strategy ETF
Nuvalent Inc

Price performance

Price movement over the last 24 hours

Key statistics

YieldMax AMZN Option Income Strategy ETF vs Nuvalent Inc — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $10.74, while Nuvalent Inc trades at $123.9 (market cap $9.80B). The key difference: Nuvalent Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

AMZYNUVL
Sector
Income / Options OverlayTechnology
52-Week High
$16.61$123.90
52-Week Low
$10.26$72.16
Market Cap
$9.80B
Enterprise Value
$8.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AMZN Option Income Strategy ETF

AMZY trades at $10.78 with no significant daily movement, showing neutral technical signals overall. The ETF maintains a consistent weekly dividend distribution strategy, though recent analyst commentary highlights concerns about NAV erosion despite high yields. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance levels cluster tightly around $10-11.

The outlook remains cautious as the synthetic option strategy delivers high income but exposes investors to amplified downside risk. While weekly distributions provide income appeal, total returns have lagged the underlying Amazon stock, creating sustainability concerns for long-term investors seeking both income and capital appreciation.

Nuvalent Inc

Nuvalent (NUVL) trades at $123.9, up 0.06% on the day, following GSK's $10.6 billion all-cash acquisition offer at $124 per share announced on June 9, 2026 (Reuters). The stock is near the acquisition price, with bullish technical signals from moving averages but overbought RSI readings. Financially, the company reports negative earnings and cash flow from operations, with a P/B ratio of 8.35. Recent news highlights multiple law firms investigating the fairness of the deal.

The acquisition by GSK provides a clear exit near current levels, limiting upside but reducing volatility. Key risks include deal completion uncertainty and shareholder litigation. Analyst sentiment is mixed with 42% buy ratings. Investors should weigh the guaranteed offer against fundamental weaknesses and legal scrutiny.

Returns comparison

Trailing returns across standard periods

About YieldMax AMZN Option Income Strategy ETF

AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.

Read more on AMZY

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL